CLINICAL TRIALS PROFILE FOR NELARABINE
✉ Email this page to a colleague
All Clinical Trials for NELARABINE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002970 ↗ | 506U78 in Treating Patients With Refractory Hematologic Cancer | Completed | Children's Cancer Group | Phase 2 | 1997-06-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
NCT00002970 ↗ | 506U78 in Treating Patients With Refractory Hematologic Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-06-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
NCT00003545 ↗ | 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Completed | Southwest Oncology Group | Phase 2 | 1998-08-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. |
NCT00003545 ↗ | 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1998-08-01 | Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. |
NCT00003635 ↗ | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-01-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents. |
NCT00003635 ↗ | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents | Completed | GlaxoSmithKline | Phase 2 | 1999-01-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NELARABINE
Condition Name
Clinical Trial Locations for NELARABINE
Trials by Country
Clinical Trial Progress for NELARABINE
Clinical Trial Phase
Clinical Trial Sponsors for NELARABINE
Sponsor Name